Eric Parker has more than 31 years of drug discovery and early development experience in big pharma (BMS, Schering-Plough, Merck), biotech (Kallyope) and as a consultant for numerous biotech and venture firms. He has led multiple neurodegenerative disease drug discovery and development programs, including the BACE inhibitor verubecestat for the treatment of Alzheimer’s disease, the adenosine A2A receptor antagonist preladenant for the treatment of Parkinson’s disease and cancer (currently in Phase 3) and the marketed NK1 antagonist rolapitant for the treatment of nausea and vomiting. Eric is the author on >100 scientific articles and serves on several scientific advisory boards. He was chosen as a Merck Presidential Fellow in 2010 and received PhRMA’s Research and Hope Award in 2012 for his work on Alzheimer’s disease. Eric holds a BS in pharmacy and a PhD in pharmacology from the University of North Carolina at Chapel Hill.